National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$52.95
add to cart

Rights & Permissions

topleft topright

Vaccines for the 21st Century: A Tool for Decisionmaking (2000)
Institute of Medicine (IOM)

Citation Manager

. "Overview of Analytic Approach and Results." Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press, 2000.

Please select a format:

BibTeX EndNote RefMan


Page
62
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Vaccines for the 21st Century: A Tool for Decisionmaking

BOX 4–1 Illustrating the Calculation of a Vaccine’s Health Benefits

The basic features of the calculation of QALYs can be illustrated with a simple scenario. Assume 100,000 cases of an illness X, occurring at an equal rate at all ages and no deaths. Half of the cases of disease result in a mild illness determined to have an HUl-based quality-adjustment weight of .90 and half in a moderate illness with a quality adjustment weight of .70. Either form of illness is assumed to last 2 weeks (.0384 years).

The quality-adjustment weights for illness X must be adjusted for the underlying health status of the population. Using survey-based data on general health status, the average quality-adjustment weight for the health status of the population without this illness is .896. Thus the adjustment weight for the mild form of illness becomes .806 (.90 • .896) and the weight for the moderate form of illness becomes .627 (.70 • .896).

To calculate QALYs, these adjustment weights are multiplied by the time spent with the illness. With a 2-week duration, a case of mild illness occurring in a given year accounts for .031 QALYs (.806 • .0384). With the same 2-week duration, a case of moderate illness accounts for .024 QALYs (.627• .0384). For an individual in the general population not experiencing this illness, the same 2-week period would represent .034 QALYs (.896 • .0384).

Use of a vaccine that prevents illness X would result in a gain of .003 QALYs for a case of mild illness (.034–.031) and .010 QALYs for a case of moderate illness (.034–.024). With cases distributed evenly between mild and moderate illness, the average gain would be .007 QALYs [(.5 • .003) + (.5 • .010)]. With 100,000 cases per year, the annual gain for the population would amount to 700 QALYs (.007 • 100,000). (The complete analysis would also require discounting QALYs for the interval between age at vaccination and average age of onset of illness X.)

Quality Adjustments: Weighting

To calculate QALYs, a quality-adjustment weight is applied to each period of time during which a person experiences a changed health state due to a particular condition, and these quality-adjusted time periods are added together. In theory, “perfect health” carries a weight of 1.0, giving full value to periods to which it applies. Death carries a weight of 0.0. A health state judged to be equivalent in quality to death would also have a weight of 0.0, meaning that time spent in that health state would have a QALY value of 0.0. A condition considered worse than death can be assigned a negative weight. These quality-adjusted periods can be summed over a person’s expected lifetime (or some other specified period of time).

Page
62
Front Matter (R1-R12)
Executive Summary (1-10)
Introduction (11-16)
Progress in Vaccine Development (17-38)
Considerations of Candidate Vaccines (39-52)
Overview of Analytic Approach and Results (53-92)
Review of the Analytical Model (93-108)
Ethical Considerations and Caveats (109-122)
Observations (123-132)
References (133-142)
Appendix 1: Borrelia burgdorferi (143-148)
Appendix 2: Chlamydia (149-158)
Appendix 3: Coccidioides Immitis (159-164)
Appendix 4: Cytomegalovirus (165-172)
Appendix 5: Enterotoxigenic E. coli (173-176)
Appendix 6: Epstein-Barr Virus (177-180)
Appendix 7: Helicobacter pylori (181-188)
Appendix 8: Hepatitis C (189-194)
Appendix 9: Herpes Simplex Virus (195-206)
Appendix 10: Histoplasma capsulatum (207-212)
Appendix 11: Human Paillomavirus (213-222)
Appendix 12: Influenza A and B (223-232)
Appendix 13: Insulin-Dependent Diabetes Mellitus (233-238)
Appendix 14: Melanoma (239-244)
Appendix 15: Multiple Sclerosis (245-250)
Appendix 16: Mycobacterium tuberculosis (251-256)
Appendix 17: Neisseria gonnorrhea (257-266)
Appendix 18: Neisseria meningitidis (267-272)
Appendix 19: Parainfluenza Virus (273-278)
Appendix 20: Respiratory Syncytial Virus (279-284)
Appendix 21: Rheumatoid Arthritis (285-290)
Appendix 22: Rotavirus (291-294)
Appendix 23: Shigella (295-298)
Appendix 24: Streptococcus, Group A (299-304)
Appendix 25: Streptococcus, Group B (305-312)
Appendix 26: Streptococcus pneumoniae (313-322)
Appendix 27: Information on accessing Electronic Spreadsheets (323-324)
Appendix 28: Summary of Workshops (325-434)
Appendix 29: Questions Posed to Outside Experts and List of Responders (435-442)
Index (443-460)